At present, anti‐PD‐1/PD‐L1 antibodies have made major breakthroughs in tumor immunotherapy, but their efficacy on solid tumors is not good, and novel efficacy strategies for combination therapy need to be identified. The gene discussed is CD274; the disease is neoplasm.